Introduction
The emergence of antimicrobial resistance among microorganisms is a serious medical problem attributed in large part to the misuse and overuse of antimicrobials. 1 In the last 15 years, development and marketing of novel antimicrobial agents have become very expensive, 2 making it imperative that new approaches to the therapy of infectious diseases be tried. Development of potentiators of known antimicrobials would be an appealing approach if it allowed increased efficacy of antibiotics and a reduction in doses, thus also reducing the likelihood of resistance development and reducing toxicity problems.
Liposomes, the most studied colloidal drug delivery systems, could be one way of improving the effectiveness of antibiotics. The best known advantages of liposomes are altered pharmacokinetics and biodistribution of the encapsulated drug molecules, giving rise to improved efficacy and/or reduced toxicity of chemotherapy. [3] [4] [5] Liposome-encapsulated antimicrobial agents have been successfully used in humans and/or in animal models against protozoal, 6 ,7 fungal 8-10 and bacterial [11] [12] [13] infections. Such experimental studies have been performed with 'rigid' liposomes, composed primarily of natural phospholipids and cholesterol, which can be polymer-coated. Liposomal formulations that include cholesterol neces-sarily have a high phase transition temperature (T C ), which makes the liposomes rigid and strong. Drugs entrapped in rigid liposomes may be more effective than free drugs in vivo, but they have generally low bactericidal activity against extracellular bacteria in vitro. 12, 13 The superior therapeutic effect of liposome-encapsulated drugs may result from the liposomes being delivered to the infection site and then degraded, releasing the entrapped antibiotic. Experimental models of infections in which antimicrobial agents encapsulated in rigid liposomes have been successful in both in-vivo and in-vitro studies all involved infections of cells of the mononuclear phagocyte system (MPS) by facultative or obligate intracellular pathogens. 14, 15 In these studies, uptake of rigid liposomes by phagocytes was essential to obtain a superior therapeutic effect.
Recently, the potential to deliver antibiotic to extracellular infections using rigid and fluid liposomal formulations was investigated in an experimental model of Pseudomonas aeruginosa chronic pulmonary infection in rats. 16, 17 Eradication of the infection was observed with antibiotic encapsulated in a fluid liposomal preparation, while antibiotic encapsulated in rigid liposomal preparations, and free antibiotic and controls, were not bactericidal. 17 The aim of the present study was to test the bactericidal efficacy of the fluid liposomal preparation: (i) against other bacteria that are particularly difficult to treat and related to P. aeruginosa, in this instance Stenotrophomonas maltophilia and Burkholderia cepacia and (ii) against other unrelated but common causes of infection, notably Escherichia coli and Staphylococcus aureus, and to evaluate the long-term stability of liposome-associated antibiotic at 4°C, room temperature and 37°C.
Materials and methods

Bacterial strains
Clinical isolates of P. aeruginosa (PA 429), S. maltophilia (C6R9) B. cepacia (PD-428) and E. coli (EC HB 101 NM 88) were isolated from the sputum of patients with cystic fibrosis (Sainte-Justine Hospital, Montréal, Québec, Canada). S. aureus (LSPQ 2499) a clinically derived strain, was a generous gift from the Laboratoire de Santé Publique du Québec. Bacteria were stored at -70°C in Brain Heart Infusion broth (Difco Laboratories, Detroit, MI, USA) supplemented with 20% glycerol.
Antibiotics and susceptibility testing
Tobramycin was obtained from Eli Lilly (Toronto, Ontario, Canada). All bacterial strains were tested for antibiotic susceptibility by an agar dilution method and a broth dilution method according to the protocols of the National Commitee for Clinical Laboratory Standards.
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The MIC was defined as the lowest concentration of tobramycin at which there was no visible growth of test bacteria. All MICs were confirmed by Etest (AB Biodisk, Unipath, Nepean, Canada).
Liposomes
Liposomes were prepared by a dehydration-rehydration vesicle method as previously described. 17 The liposome preparation consisted of dipalmitoylphosphatidylcholine (DPPC) and dimyristoylphosphatidylglycerol (DMPG) (Avanti Polar Lipids, Inc., Birmingham, AL, USA) in a molar ratio of 15:1, which corresponds to a global T C of 29°C. 20 Tobramycin in liposomal preparations was quantified by HPLC as previously described. 17 
Long-term release studies
Antibiotic release over a period of 28 days was studied to measure the stability of the fluid liposomal preparation, i.e. the relative quantity of the drug found in liposomes as a function of time and temperature. DPPC/DMPG liposome-encapsulated tobramycin (888 g) and an equivalent quantity of free tobramycin, used as a control, were suspended in tubes containing 12 mL of sterile PBS and shaken slowly (100 rpm) at 4°C, room temperature or 37°C for 28 days. The study was done in triplicate. Samples of 500 mL were collected at 16 h and on days 1, 2, 14, 21 and 28 and centrifuged at 5000g for 20 min in an Eppendorf centrifuge (Fisher, Montréal, Canada). After supernatant collection, the pellet was resuspended in 500 mL of PBS. Afterwards, 100 mL samples of supernatants and resuspended pellets were subjected to HPLC analysis for tobramycin determination as previously described. 17 
Experimental design
In-vitro killing curves were performed in the presence of sub-MIC concentrations of free or encapsulated tobramycin and controls consisting of free antibiotic combined with empty liposomes, liposomes containing PBS or PBS alone. Volumes of 250 mL of Proteose Peptone Broth no. 2 (Difco) were inoculated with a 17 h pre-culture of each bacterium to give a stock preparation containing a log-phase cell density of approximately 10 7 cfu/mL as evaluated initially by optical density at 660 nm. For more precise evaluation of the number of bacteria, culture dilutions were plated in triplicate and the number of cfu was counted for final evaluation of the results.
All the killing tests were performed in triplicate as follows: to 29 mL of the cultures described above was added 1 mL of either free antibiotic, liposome-encapsulated tobramycin, or controls. Quantities of tobramycin contained in liposomes were first determined by HPLC analysis after methanol extraction. 17 A second HPLC analysis was performed after the final dilutions to compare free and encapsulated antibiotic preparations. P. aeru -ginosa, S. maltophilia, B. cepacia, E. coli and S. aureus cultures received respectively 30, 1, 3, 0.75 and 1.55 mg/L of free tobramycin and 29.4, 1, 2.95, 0.75 and 1.57 mg/L of encapsulated tobramycin as determined by HPLC analysis. These values were lower than the MICs for each bacterial strain. The cultures were then incubated on a shaker at 37°C for 16 h. Samples of 1.5 mL were collected after 0, 1, 3, 6 and 16 h of incubation. One millilitre was read at 660 nm and 0.5 mL was used immediately for serial dilutions in cold sterile PBS. Appropriate dilutions were plated and cultured in triplicate on Proteose Peptone no. 2 agar (Difco). After overnight incubation at 37°C in 5% CO 2 , the number of cfu was determined.
Data analysis
All the data were analysed using Excel (Microsoft Corporation), and the results were expressed as mean values S.E.M.
Results
Stability of antibiotic-containing liposomes
The long-term release study showed that, in spite of their relative fluidity, the liposomes retained 66% of the encapsulated drug until day 28 at 4°C and room temperature (Figure 1 ). About 16% of the antibiotic was found in the supernatant from the first sample collection and reached a steady state of about 21% for the whole study. The mean loss of antibiotic was approximately onethird of the initial encapsulated drug which comprised the released antibiotic detected in the supernatant and a loss of about 12% due to handling. Though the results obtained at 4°C and at room temperature were statistically comparable, larger fluctuations were observed with liposome-encapsulated tobramycin maintained at room temperature ( Figure 1) . Analysis of the samples collected at 16 h from liposome preparations maintained at 37°C showed that the amount of antibiotic released during this time was comparable to that observed in the same time at 4°C and room temperature. After 16 h, though, liposomes maintained at 37°C showed sustained significant release of tobramycin, so that by the end of the study, only 8% of the drug was still encapsulated in the liposomes incubated at 37°C (Figure 1 ). Free tobramycin used as a reference showed that the measure of tobramycin by HPLC was not significantly influenced by temperature variations over the whole test period (data not shown).
In-vitro bactericidal efficacy of liposomeencapsulated versus free tobramycin
The MICs of tobramycin for P. aeruginosa, S. maltophilia, B. cepacia, E. coli and S. aureus were 60, 2, 5, 1.5 and 2 mg/L respectively. As indicated in Materials and methods, the doses of encapsulated tobramycin were equivalent to or lower than the doses of free tobramycin and lower than the MIC for the five bacterial strains tested. Killing curves of bacteria were evaluated by counting cfu on agar plates (Figure 2a-e) . Controls consisting of liposomes without antibiotic and liposomes combined with free antibiotic are not included in the figures because of the superimposition of these results with PBS controls and free tobramycin.
Three hours after treatment of B. cepacia, E. coli and S. aureus cultures with liposome-encapsulated antibiotic, the reduction in growth was respectively of 129, 84 and 566 times greater than that in cultures treated with free antibiotic (Figure 2c, d and e) . At 6 h and/or 16 h after treatment, a decrease in cfu/mL was observed for all the strains treated with liposome-encapsulated tobramycin (Figure  2a-e) while bacterial growth reached approximately 10 8 -10
9 cfu/mL in PBS control cultures. Following the addition of free antibiotic, the growth of the P. aeruginosa group was minimally affected whereas a considerable decrease in growth was observed between 1 h and 6 h for E. coli and S. aureus (Figure 2d and e) . However, the same quantity of encapsulated antibiotic showed cfu decreases of S. aureus and E. coli of more than 10 4 times and 166 times respectively compared with free antibiotic (Figure 2e ).
Sixteen hours after treatment, a significant increase in growth of B. cepacia, E. coli and S. aureus cultures was noted for those cultures treated with encapsulated antibiotic were noted, but the cfu counts were still 35, 166 and 163 times lower respectively than the cfu counts in cultures treated with free antibiotic (Figure 2c, d and e) .
Discussion
In previous studies, in-vitro drug release kinetics and pulmonary retention of encapsulated antibiotic in liposomes and the effect of their lipid composition in terms of bilayer fluidity and charge were investigated. 20 Fluid liposomes composed of DPPC and DMPG showed modulated release of antibiotic in vitro while maintaining good pulmonary persistence of the drug. Later, tobramycin encapsulated in liposomes with a T C of 29°C or 32°C, as opposed to more rigid liposomes, was shown to eradicate mucoid P. aeruginosa in an animal model of chronic pulmonary infection. 17 The present in-vitro study showed that liposomes with this formulation (T C = 29°C) and containing a sub-MIC tobramycin concentration, were markedly bactericidal, not only against P. aeruginosa but also against all other strains tested. Broad antibacterial activity of liposomes was demonstrated by the efficacy of the encapsulated antibiotic against E. coli and S. aureus, whose cell walls are structurally very different from those of Pseudomonas spp.
To ensure that the doses of tobramycin administered in this study were accurate and reliable, two independent HPLC analyses were performed on free and encapsulated tobramycin before and after final dilutions. The results obtained following the use of sub-MIC quantities of encapsulated tobramycin against three related strains of the Pseudomonas group are striking since this group is recognized for its very low nonspecific permeability and/or the presence of an efflux pump in its external membrane. [21] [22] [23] The maximal bactericidal activity of the encapsulated antibiotic was observed at 6-16 h for P. aeruginosa and S. maltophilia (Figure 2a and b) . The bactericidal effect occurred more quickly (between 1 and 3 h) in B. cepacia, E. coli and S. aureus (Figure 2c, d and e) . This may be explained at least in part by the remarkable impermeability of the Pseudomonas outer membrane, which is a major obstacle to antibiotic penetration. 23 The lipopolysaccharide side chains of Enterobacteriacae such as E. coli are crosslinked, conferring an intermediate degree of impermeability to their outer membrane, 24 while the peptidoglycan layer of Gram-positive bacteria generally is not a significant barrier to antibiotic entry. 23 This, together with shorter generation times, 25 can also explain why these differences are seen.
The fact that sub-MIC concentrations of encapsulated antibiotic reduced the growth of bacteria by 35-10 5 times in comparison with cultures treated with the same quantity of free antibiotic suggests a direct interaction of liposomes with bacteria. It is possible that, due to the fluidity or plasticity of the DPPC/DMPG liposomal formulation, the liposomes could fuse with the bacterial cells. Such a fusion process would increase the amount of antibiotic that penetrated bacterial cell walls. Preliminary findings from studies under way in our laboratory seem to support this hypothesis (data not shown).
The results of the long-term release study indicate that antibiotic-containing liposomes are relatively stable at 4°C and room temperature. Indeed, more than 66% of the antibiotic was recovered from the liposomes at the end of the 28 day period (Figure 1) . However, at room temperature, some instability seemed to occur (Figure 1 ), perhaps because this temperature is close to the T C of the liposomes (29°C), so fluctuation in room temperature might have caused transitions between the solid and liquid-crystalline phases. Consequently, at room temperature the phospholipids seemed to be shifting continuously between the two states ( Figure 1) . The study performed at 37°C, 8° above the T C of the liposomes, showed that until 16 h, liposomes still retained the same quantity of the drug as noted for liposomes maintained at 4°C and room temperature (Figure 1) . Thus, despite being highly labile, liposomes can retain the drug for a sufficient period of time to allow effective interactions. As noted above, this liposomal plasticity could promote fusion with bacterial cell walls. The plausibility of such a process is in accordance with the fact that the liposomes, even if they contained sub-MIC concentrations of tobramycin, showed significant bactericidal activity at 37°C against a broad range of bacteria.
The major mechanisms conferring antibiotic resistance are: preventing the drug from entering the cell, rapid extrusion of the drug, or enzymatic inactivation of the , bacteria exposed to free tobramycin; ---, bacteria exposed to PBS (controls); , bacteria exposed to liposome-entrapped tobramycin. MICs of tobramycin for P. aeruginosa, S. maltophilia, B. cepacia, E. coli and S. aureus were found to be 60, 2, 5, 1.5 and 2 mg/L respectively. Results are expressed as the arithmetic mean of the three samples S.E.M. drug or alteration of its molecular target. 23 Recent studies suggest that mechanisms of resistance work synergically, with decreased permeability and/or the presence of membrane-associated energy driven efflux systems playing an important role in the phenomenon. 23, 26, 27 For example. it is well known that in Gram-negative bacteria, both enzymatic modification of the drug and impermeability of the outer membrane contribute to resistance. 24, 28 Low affinity for the molecular target of the drug or accelerated penetration of the drug reduce the capacity of enzymes to protect the bacteria. 24 If we consider the importance of the penetration barrier in antibiotic resistance in bacteria, the data obtained with the DPPC/DMPG liposomal formulation suggest that the liposome-encapsulated antibiotic described could not only increase the efficacy of antibiotic treatments with non-resistant strains but could also contribute to overcoming bacterial resistance. Work is in progress to measure the efficacy of this liposomal formulation against multidrug-resistant mutants.
